News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
301,434 Results
Type
Article (15309)
Company Profile (34)
Press Release (286088)
Multimedia
Podcasts (29)
Webinars (5)
Section
Business (80731)
Career Advice (1342)
Deals (16017)
Drug Delivery (36)
Drug Development (48556)
Employer Resources (54)
FDA (7804)
Job Trends (6518)
News (151634)
Policy (12650)
Tag
Academia (1009)
Accelerated approval (8)
Adcomms (13)
Allergies (79)
Alliances (15328)
ALS (79)
Alzheimer's disease (811)
Antibody-drug conjugate (ADC) (140)
Approvals (7953)
Artificial intelligence (203)
Autoimmune disease (34)
Automation (12)
Bankruptcy (118)
Best Places to Work (5668)
BIOSECURE Act (4)
Biosimilars (91)
Biotechnology (25)
Bladder cancer (100)
Brain cancer (33)
Breast cancer (365)
Cancer (2614)
Cardiovascular disease (208)
Career advice (1044)
Career pathing (11)
CAR-T (119)
CDC (13)
Cell therapy (325)
Cervical cancer (22)
Clinical research (43389)
Collaboration (749)
Company closure (2)
Compensation (580)
Complete response letters (27)
COVID-19 (1258)
CRISPR (40)
C-suite (242)
Cystic fibrosis (58)
Data (3083)
Denatured (1)
Depression (54)
Diabetes (285)
Diagnostics (2797)
Digital health (19)
Diversity (1)
Diversity, equity & inclusion (11)
Drug discovery (96)
Drug pricing (41)
Drug shortages (10)
Duchenne muscular dystrophy (120)
Earnings (52213)
Editorial (17)
Employer branding (8)
Employer resources (47)
Events (49086)
Executive appointments (505)
FDA (9430)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (8)
Funding (666)
Gene editing (84)
Generative AI (9)
Gene therapy (273)
GLP-1 (532)
Government (1704)
Grass and pollen (5)
Guidances (317)
Healthcare (8188)
HIV (33)
Huntington's disease (23)
IgA nephropathy (39)
Immunology and inflammation (113)
Immuno-oncology (11)
Indications (40)
Infectious disease (1385)
Inflammatory bowel disease (95)
Inflation Reduction Act (6)
Influenza (54)
Intellectual property (96)
Interviews (251)
IPO (9721)
IRA (14)
Job creations (1190)
Job search strategy (911)
Kidney cancer (12)
Labor market (35)
Layoffs (240)
Leadership (14)
Legal (2053)
Liver cancer (61)
Longevity (5)
Lung cancer (385)
Lymphoma (210)
Machine learning (12)
Management (17)
Manufacturing (259)
MASH (100)
Medical device (6010)
Medtech (6019)
Mergers & acquisitions (6883)
Metabolic disorders (660)
Multiple sclerosis (96)
NASH (17)
Neurodegenerative disease (110)
Neuropsychiatric disorders (26)
Neuroscience (1392)
NextGen: Class of 2025 (2418)
Non-profit (2098)
Now hiring (10)
Obesity (285)
Opinion (102)
Ovarian cancer (87)
Pain (92)
Pancreatic cancer (123)
Parkinson's disease (141)
Partnered (5)
Patents (192)
Patient recruitment (181)
Peanut (38)
People (13846)
Pharmaceutical (14)
Pharmacy benefit managers (8)
Phase I (10843)
Phase II (17833)
Phase III (18396)
Pipeline (2132)
Policy (70)
Postmarket research (1374)
Preclinical (3696)
Press Release (18)
Prostate cancer (142)
Psychedelics (18)
Radiopharmaceuticals (131)
Rare diseases (342)
Real estate (1552)
Recruiting (21)
Regulatory (10775)
Reports (31)
Research institute (935)
Resumes & cover letters (256)
Rett syndrome (9)
RNA editing (5)
RSV (44)
Schizophrenia (90)
Series A (97)
Series B (76)
Service/supplier (5)
Sickle cell disease (47)
Special edition (19)
Spinal muscular atrophy (106)
Sponsored (19)
Startups (1093)
Stomach cancer (6)
Supply chain (53)
Tariffs (31)
The Weekly (28)
Vaccines (467)
Venture capital (35)
Weight loss (167)
Women's health (26)
Worklife (10)
Date
Today (101)
Last 7 days (343)
Last 30 days (1530)
Last 365 days (21588)
2025 (15914)
2024 (20537)
2023 (21229)
2022 (25568)
2021 (26883)
2020 (25280)
2019 (20186)
2018 (15167)
2017 (15632)
2016 (13557)
2015 (16116)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
Location
Africa (378)
Alabama (28)
Alaska (3)
Arizona (56)
Arkansas (8)
Asia (21189)
Australia (3948)
California (6080)
Canada (1611)
China (567)
Colorado (243)
Connecticut (270)
Delaware (190)
Europe (43928)
Florida (745)
Georgia (180)
Hawaii (2)
Idaho (19)
Illinois (443)
India (25)
Indiana (240)
Iowa (10)
Japan (254)
Kansas (61)
Kentucky (12)
Louisiana (10)
Maine (39)
Maryland (630)
Massachusetts (4292)
Michigan (104)
Minnesota (310)
Mississippi (4)
Missouri (62)
Montana (12)
Nebraska (6)
Nevada (74)
New Hampshire (39)
New Jersey (1693)
New Mexico (8)
New York (1551)
North Carolina (744)
North Dakota (4)
Northern California (2826)
Ohio (153)
Oklahoma (6)
Oregon (15)
Pennsylvania (1141)
Puerto Rico (10)
Rhode Island (19)
South America (545)
South Carolina (21)
Southern California (2350)
Tennessee (79)
Texas (894)
United States (20707)
Utah (136)
Virginia (145)
Washington D.C. (37)
Washington State (503)
West Virginia (2)
Wisconsin (68)
Wyoming (1)
301,434 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Bayer Makes Potential $1.3B Cancer Bet in Kumquat Deal
For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat Biosciences’ small-molecule KRAS G12D blocker.
August 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
September 4, 2025
·
3 min read
Press Releases
Teva Releases Q3 2025 Aide Memoire
September 25, 2025
·
2 min read
Press Releases
Organogenesis Provides Update on Second Phase 3 ReNu® Study
September 25, 2025
·
6 min read
Press Releases
Press release: Availability of the Q3 2025 Aide mémoire
September 24, 2025
·
4 min read
Press Releases
Evaxion out-licenses vaccine candidate EVX-B3 to MSD
September 25, 2025
·
6 min read
Press Releases
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
June 23, 2025
·
8 min read
Press Releases
SEED Therapeutics Completes $30 Million Series A-3 Financing
September 23, 2025
·
2 min read
Huntington’s disease
UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout
If approved, uniQure’s gene therapy AMT-130—which slowed disease progression by 75%—would be the first genetic treatment for Huntington’s disease. A BLA submission is planned for the first quarter of 2026.
September 24, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Q3 Saw Some of the Highest-Value Biopharma Acquisitions of the Year So Far
J&J still holds the top deal of the year by value with its $14.6 billion buy of Intra-Cellular in January, but the next four biggest acquisitions came in the past four months.
October 1, 2025
·
2 min read
·
Annalee Armstrong
1 of 30,144
Next
